CN102301236B - 方法 - Google Patents

方法 Download PDF

Info

Publication number
CN102301236B
CN102301236B CN200980155784.2A CN200980155784A CN102301236B CN 102301236 B CN102301236 B CN 102301236B CN 200980155784 A CN200980155784 A CN 200980155784A CN 102301236 B CN102301236 B CN 102301236B
Authority
CN
China
Prior art keywords
exosomes
cancer
purposes
exosome
experimenter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980155784.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN102301236A (zh
Inventor
A.克莱顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Biomedica UK Ltd
Original Assignee
Oxford Biomedica UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Biomedica UK Ltd filed Critical Oxford Biomedica UK Ltd
Publication of CN102301236A publication Critical patent/CN102301236A/zh
Application granted granted Critical
Publication of CN102301236B publication Critical patent/CN102301236B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
CN200980155784.2A 2008-12-15 2009-12-15 方法 Expired - Fee Related CN102301236B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0822836.3A GB0822836D0 (en) 2008-12-15 2008-12-15 Method
GB0822836.3 2008-12-15
PCT/GB2009/002885 WO2010070276A1 (en) 2008-12-15 2009-12-15 Method

Publications (2)

Publication Number Publication Date
CN102301236A CN102301236A (zh) 2011-12-28
CN102301236B true CN102301236B (zh) 2014-06-25

Family

ID=40326133

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980155784.2A Expired - Fee Related CN102301236B (zh) 2008-12-15 2009-12-15 方法

Country Status (6)

Country Link
US (1) US20120027749A1 (https=)
EP (1) EP2370818A1 (https=)
JP (1) JP5671475B2 (https=)
CN (1) CN102301236B (https=)
GB (1) GB0822836D0 (https=)
WO (1) WO2010070276A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888035B2 (en) 2008-10-30 2011-02-15 Caris Mpi, Inc. Methods for assessing RNA patterns
WO2010056337A2 (en) 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
US20130052647A1 (en) * 2010-02-10 2013-02-28 Marianna Goldrick Methods for fractionating and processing microparticles from biological samples and using them for biomarker discovery
EP2542696B1 (en) 2010-03-01 2016-09-28 Caris Life Sciences Switzerland Holdings GmbH Biomarkers for theranostics
JP2013526852A (ja) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
KR20140067001A (ko) * 2011-08-08 2014-06-03 카리스 라이프 사이언스 룩셈부르크 홀딩스, 에스.에이.알.엘. 생물지표 조성물 및 방법
RU2014115999A (ru) * 2011-09-22 2015-10-27 Универсидад Де Лос Андес Способ мониторинга, диагностики и/или прогнозирования острого повреждения почек на ранней стадии
KR101716555B1 (ko) * 2012-01-24 2017-03-14 화이자 인코포레이티드 포유동물 대상체에서 5t4-양성 순환 종양 세포를 검출하는 방법 및 5t4-양성 암을 진단하는 방법
JP5969777B2 (ja) * 2012-03-07 2016-08-17 国立研究開発法人医薬基盤・健康・栄養研究所 肺腺扁平上皮癌の腫瘍マーカー及び診断キット
SG10201404895XA (en) * 2014-08-13 2016-03-30 Agency Science Tech & Res Diagnosis
CN105388055B (zh) * 2015-12-11 2018-03-27 浙江省肿瘤医院 从尿液中分离肿瘤细胞来源的外泌体的方法
CN105505877B (zh) * 2015-12-11 2018-09-28 浙江省肿瘤医院 恶性胸腔积液中分离肿瘤细胞来源的外泌体的方法
US10874610B2 (en) 2016-10-19 2020-12-29 Northwestern University Extracellular vesicle-based diagnostics and engineered exosomes for targeted therapeutics against cancer
TWI682176B (zh) * 2017-09-18 2020-01-11 國立臺灣大學 用於甲狀腺癌預後之生物標記
JP2023525581A (ja) * 2020-05-15 2023-06-16 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体の活性化を検出するための細胞外小胞の使用方法、並びに補体性疾患の処置を評価及び／又は監視するためのその使用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1724585A1 (en) * 2005-05-21 2006-11-22 ProteoSys AG Annexin for cancer risk assessment
CN101027099A (zh) * 2004-02-16 2007-08-29 蛋白质系统股份公司 用于癌症的诊断标记物
CN101035564A (zh) * 2004-09-10 2007-09-12 惠氏公司 人源化的抗5t4抗体和抗5t4抗体/加利车霉素缀合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0403559A1 (en) * 1988-03-04 1990-12-27 Cancer Research Campaign Technology Limited Improvements relating to antigens
AU2001285157A1 (en) * 2000-08-28 2002-03-13 Oncomedx, Inc. 5t4 rna in plasma and serum as a marker for neoplastic disease
SE0102327D0 (sv) * 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
JP5068543B2 (ja) * 2004-02-16 2012-11-07 プロテオジス アクチェンゲゼルシャフト がんに関する診断マーカー
EP1782070B1 (en) * 2004-06-17 2010-09-08 MannKind Corporation Tumor-associated antigen profiles in cancer diagnostics and immunotherapy
EP1724586A3 (en) * 2005-05-21 2007-07-04 ProteoSys AG Annexin for cancer risk assessment
KR101810799B1 (ko) * 2008-02-01 2017-12-19 더 제너럴 하스피탈 코포레이션 의학적 질환 및 병태의 진단, 예후, 및 치료에 있어서 미세소포체의 용도
WO2010056337A2 (en) * 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
GB201018480D0 (en) * 2010-11-02 2010-12-15 Oxford Biomedica Ltd Factors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101027099A (zh) * 2004-02-16 2007-08-29 蛋白质系统股份公司 用于癌症的诊断标记物
CN101035564A (zh) * 2004-09-10 2007-09-12 惠氏公司 人源化的抗5t4抗体和抗5t4抗体/加利车霉素缀合物
EP1724585A1 (en) * 2005-05-21 2006-11-22 ProteoSys AG Annexin for cancer risk assessment

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Human tumor-derived exosomes selectively impair lymphocyte responses to interieukin-2;CLAYTON ALED ET AL;《CANCER RESEARCH》;20070831;第67卷(第15期);7458-7466 *
Identification and proteomic profiling of exosomes in human urine;PISITKUN TRAIRAK ET AL;《PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA》;20040907;第101卷(第36期);13368-13373 *

Also Published As

Publication number Publication date
GB0822836D0 (en) 2009-01-21
CN102301236A (zh) 2011-12-28
US20120027749A1 (en) 2012-02-02
JP2012512389A (ja) 2012-05-31
EP2370818A1 (en) 2011-10-05
WO2010070276A1 (en) 2010-06-24
JP5671475B2 (ja) 2015-02-18

Similar Documents

Publication Publication Date Title
CN102301236B (zh) 方法
Welton et al. Proteomics analysis of bladder cancer exosomes
Sequeiros et al. Targeted proteomics in urinary extracellular vesicles identifies biomarkers for diagnosis and prognosis of prostate cancer
CN101460630B (zh) He4与其它生化标记物在卵巢癌评估中的应用
EP3143405B1 (en) Methods and kits for the diagnosis of lung cancer
US20190310172A1 (en) Profiling extracellular vesicles
CN105658810B (zh) 用于检测前列腺癌的方法
KR102596374B1 (ko) 대장암을 검출하기 위한 바이오마커
CA3167721A1 (en) Compositions and methods for detection of ovarian cancer
US12429486B2 (en) Use of Tenascin-C as an extracellular marker of tumor-derived microparticles
CN102687011A (zh) 癌症生物标志物及其应用
WO2021045224A1 (ja) がん免疫療法等における免疫関連有害事象の予測
KR101388711B1 (ko) 암 진단 마커로서의 보체 ｃ９
CN107110848B (zh) 以脱氧羟腐胺缩赖氨酸合酶基因作为指标使用的动脉硬化及癌的检测方法
JP6361943B2 (ja) 補体因子ｂタンパク質に特異的に結合する抗体及び糖鎖抗原１９−９タンパク質に特異的に結合する抗体を含む膵臓癌診断用キット
US20150338412A1 (en) Composition for diagnosis of lung cancer and diagnosis kit for lung cancer
JP2024516783A (ja) がんのバイオマーカーおよび治療標的としてのシトルリン化タンパク質
US20230221252A1 (en) Methods and devices for characterizing nanovesicles and bound or associated targets thereof
CN103257227B (zh) 改进的免疫测定方法
KR101289454B1 (ko) 소세포폐암 및 비소세포폐암 진단 마커로서의 보체 ｃ９
WO2024203968A1 (ja) がんを検出する方法、がんの予後を予測する方法、バイオマーカー及びその使用方法、並びに、がんの検出用又はがんの予後の予測用キット
EP2772759A1 (en) Composition for diagnosis of lung cancer
WO2011138955A1 (ja) Ｓｉａα２－８Ｓｉａα２－３Ｇａｌβ－Ｒ糖鎖を持つムチン１の分析方法
Risha The proteomic analysis of exosomes from breast cell lines reveals potential biomarkers of breast cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140625

Termination date: 20181215

CF01 Termination of patent right due to non-payment of annual fee